Target conditions include autoimmune diseases 12, 13, allergic diseases 14, degenerative inflammatory diseases ( e.g., atherosclerosis) 15, degenerative retinal diseases 16 and chronic dry eye 17. Rvs and their precursors are potential drug candidates for treating a broad range of acute and chronic diseases caused by a failure to resolve inflammation 11. Specifically, they limit inflammation by inhibiting key immunological processes in response to infection, injury and/or environmental challenges 8 while preserving tissue integrity and promoting tissue repair 9, 10. Resolvins (Rvs), which are highly potent lipid mediators, offer a viable alternative for better treating SS. resolvins) to regulate inflammation has demonstrated significantly effective responses in treating many inflammatory related diseases 7. An alternative approach using endogenous lipid mediators ( e.g. Therefore, it is unlikely that treatment with only anti-inflammatory drugs would achieve the ultimate goal of a “cure” however, combinations with other potent therapies could control inflammation by targeting endogenous pathways. steroids) showed promising results by suppressing inflammatory responses, but consequently pre-terminates pro-inflammatory responses that are essential for tissue resolution 5, 6. Current therapies, such as anti-inflammatory drugs ( e.g. Resolution of inflammation is a tightly regulated process in the body with specific checkpoints that must be met for proper resolution 4. Despite not knowing the exact cause(s) of SS, resolution of the inflammation and/or alleviation of disease progression is the ultimate goal for current researchers. So far, the well-defined condition among all patients is chronic inflammation of the exocrine tissues. There are several hypotheses suggesting that genetic variants or environmental components may lead to SS, though the pathogenesis is likely due to a combination of many factors 3. Although extensive investigation has been done to understand SS 2, the causes of the disease are yet unknown and treatments remain largely ineffective. Sjögren’s syndrome (SS) is an autoimmune disease affecting approximately 1% of the general population and up to 3% of people over the age of fifty 1, with women accounting for more than 90% of diagnosed cases. Finally, AT-RvD1 decreases lymphocytic infiltration into the salivary glands when used with small doses of the steroid, dexamethasone, and promotes the tissue healing process. Our results indicate that systemic treatment with AT-RvD1 diminishes the progression of the disease in salivary epithelium from female mice as follows: (a) improves secretory function, (b) reduces pro-inflammatory molecule gene expression, (c) increases anti-inflammatory molecule gene expression and (d) induces M2 macrophage polarization. The goal of this study was to determine whether systemic preventive treatment with Aspirin-triggered RvD1 (AT-RvD1) reduces inflammation and preserves secretory functioning in NOD/ShiLtJ SS-like mice. Resolvins (Rv), which are highly potent lipid mediators, offer a viable alternative for better treating inflammatory diseases such as SS. In light of the high degree of need and the limitations of current therapies, development of alternative treatments to restore functioning is essential. Treatments for hyposalivation are limited to the use of saliva substitutes and medications that provide only temporary relief. Sjögren’s syndrome (SS) is a chronic inflammatory autoimmune disease characterized by diminished secretory function of the exocrine glands.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |